The US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) approved Johnson & Johnson’s Spravato (esketamine) in 2019 for treatment-resistant depression, the first approval of a psychedelic treatment for a psychiatric disorder in both the US and the European Union. Esketamine is derived from the anesthetic ketamine. This opened the floodgates of interest in psychedelic space. To date, two psilocybin-based drugs have received FDA breakthrough designation – UK’s COMPASS Pathways for treatment-resistant depression and US’ Usona Institute for major depressive disorder.
This, along with the fact that mental health disorders have risen exponentially but the development of novel medications has not kept pace. Drugs such as use of MDMA (3-4 methylenedioxymethamphetamine), psilocybin, and LSD (lysergic acid diethylamide) are traditionally considered to be recreational but are increasingly being used in medical research.
A report from Research And Markets says that the psychedelic drugs market size is projected to reach $10.75 billion by 2027, from $4.75 billion in 2020 growing at a CAGR of 12.36 per cent during 20212027.
‘‘The whole field is advancing in industry and academia, with many new groups in neuropsychopharmacology around the world developing and using techniques from animal models, to human studies with MRI to map neural networks in order to better understand the mechanisms of action. Add to that psychotherapy research and training to better apply these methods in combination with psychoactive compounds to achieve outcomes that exceed use of the drug alone. I think that the R&D is reaching a critical mass and really impactful innovations are not so far out,’’ said Dr. Nathan Bryson, Chief Scientific Officer at Field Trip Health Canada.
Unleashing potential of psychedelics
Denne historien er fra BioSpectrum Asia March 2022-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra BioSpectrum Asia March 2022-utgaven av BioSpectrum Asia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.